Neurocrine Biosciences, Inc. Live Share Price Today, Share Analysis and Chart

Name: Neurocrine Biosciences, Inc.: Is Infosys Ltd. worth buying?
Item: Neurocrine Biosciences, Inc.
Rating: 2.151555625
Author: Trendlyne DVM scores

Turnaround Potential

about

Neurocrine Biosciences Inc engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's products include INGREZZA for tardive ...

133.51 4.77 (3.71%)

58.51% Gain from 52W Low

1.3M

XNAS Volume

XNAS 09 Jul, 2025 5:30 PM (EDT)

Medium Financial Strength

38.9 / 100

Mid Valuation

33.7 / 100

Technically Moderately Bullish

60.7 / 100

Turnaround Potential These stocks may be affordable or expensive due to their medium quality and a good technical scoring. However, their reasonable financials successfully attract investors. View Similar Embed DVM

160

1Yr Price target upside is 20%

25 analysts

Neurocrine Biosciences, Inc. Live Price Chart

Switch to TradingView

Loading Fundamental data..

Loading data..

Neurocrine Biosciences, Inc. Live Share Price Today, Share Analysis and Chart

Neurocrine Biosciences Inc engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's products include INGREZZA for tardive ...

58.51% Gain from 52W Low

SWOT Analysis

Neurocrine Biosciences, Inc. Live Price Chart